Please try another search
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus. In addition, the company develops SM06, a humanised Anti-CD22, which is in preclinical trial to treat systemic lupus erythematosus, rheumatoid arthritis, neuromyelitis optica spectrum disorder, and sjogren’s syndrome; and SM09, a humanised Anti-CD22, which is in preclinical trial to treat non-hodgkin’s lymphoma and autoimmune diseases. SinoMab BioScience Limited was incorporated in 2001 and is based in Tai Po, Hong Kong.
Name | Age | Since | Title |
---|---|---|---|
Shui On Leung | 62 | 2001 | Founder, Chairman & CEO |
Dylan Carlo Tinker | 55 | 2019 | Independent Non-Executive Director |
Xun Dong | 49 | 2019 | Non-Executive Director |
Lei Shi | 38 | 2021 | Non-Executive Director |
Haigang Chen | 41 | 2017 | Non-Executive Director |
Wenyi Liu | 37 | 2017 | Non-Executive Director |
George William Hunter Cautherley | 81 | 2019 | Independent Non Executive Director |
Ping Cho Hon | 65 | 2019 | Independent Non-Executive Director |
Chi Ming Lee | 70 | 2021 | Independent Non-Executive Director |
Jianmin Zhang | 47 | 2023 | Non-Executive Director |
Shanchun Wang | 56 | 2022 | President of China & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review